Clinical Trial Update: TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating tumor-infiltrating lymphocyte (TIL) therapy for non-small cell lung cancer. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tumor-infiltrating lymphocyte (TIL) therapy

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Non-Small Cell Lung Cancer, Lung Cancer (NSCLC) | Phase 2 | Status: RECRUITING